Literature DB >> 8991985

Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma.

A Ludwicka1, T Ohba, M Trojanowska, A Yamakage, C Strange, E A Smith, E C Leroy, S Sutherland, R M Silver.   

Abstract

OBJECTIVE: Systemic sclerosis (scleroderma, SSc) frequently affects the lungs, and interstitial pulmonary fibrosis is one of its major complications. The pathophysiology of SSc lung disease s poorly understood, but recent studies document an inflammatory process resembling that of idiopathic pulmonary fibrosis with increased numbers of activated alveolar macrophages and granulocytes in bronchoalveolar lavage (BAL) fluid). We determined levels of 2 potentially important mediators of fibroproliferative repair in BAL fluid from patients with SSc.
METHODS: Using Western blot and ELISA techniques we measured levels of platelet derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta in BAL fluid from patients with SSc and healthy controls. The mitogenic effect of these cytokines on SSc lung myofibroblasts was determined by [3H]thymidine incorporation.
RESULTS: SSc BAL fluid contains significantly elevated levels of PDGF-AA and PDGF-BB. Where TGF-beta 1 was significantly elevated in SSc lavage fluid, the amount of TGF-beta 2 was significantly less than that observed in normal lavage fluid. Myofibroblasts cultured from SSc lavage fluid exhibited enhanced [3H]thymidine incorporation upon exposure to the growth factors present in SSc BAL fluid: PDGF and TGF-beta 1. SSc lung myofibroblasts pretreated with TGF-beta 1 exhibited an enhanced mitogenic effect upon stimulation by PDGF, due in part to the induction of the PDGF alpha receptor.
CONCLUSION: Our studies support a role for PDGF and TGF-beta 1 in the pathogenesis of SSc lung disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8991985

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  47 in total

Review 1.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 2.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome.

Authors:  Jeffrey C Horowitz; Zongbin Cui; Thomas A Moore; Tamara R Meier; Raju C Reddy; Galen B Toews; Theodore J Standiford; Victor J Thannickal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-10-07       Impact factor: 5.464

Review 4.  Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Authors:  Naoki Iwamoto; Jörg H W Distler; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 5.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

6.  Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?

Authors:  Christopher G Elliott; Douglas W Hamilton
Journal:  J Cell Commun Signal       Date:  2011-04-19       Impact factor: 5.782

Review 7.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 8.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

9.  Molecular framework for response to imatinib mesylate in systemic sclerosis.

Authors:  Lorinda Chung; David F Fiorentino; Maya J Benbarak; Adam S Adler; Melissa M Mariano; Ricardo T Paniagua; Ausra Milano; M Kari Connolly; Boris D Ratiner; Robert L Wiskocil; Michael L Whitfield; Howard Y Chang; William H Robinson
Journal:  Arthritis Rheum       Date:  2009-02

10.  Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

Authors:  Andrew Leask
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.